Shattuck Labs (STTK) to Release Earnings on Wednesday

Shattuck Labs (NASDAQ:STTK) is projected to release its earnings data on Wednesday, February 26th. Analysts expect Shattuck Labs to post earnings of ($0.32) per share and revenue of $1.00 million for the quarter.

Shattuck Labs Price Performance

Shares of Shattuck Labs stock opened at $1.72 on Tuesday. The firm has a market cap of $82.11 million, a price-to-earnings ratio of -1.12 and a beta of 1.70. The stock’s 50-day moving average is $1.21 and its 200-day moving average is $1.83. Shattuck Labs has a one year low of $0.94 and a one year high of $11.76.

Analysts Set New Price Targets

STTK has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research report on Friday, November 15th. Four investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Shattuck Labs currently has an average rating of “Hold” and an average price target of $8.67.

Insider Buying and Selling at Shattuck Labs

In other Shattuck Labs news, Director Redmile Group, Llc acquired 133,371 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were purchased at an average price of $1.25 per share, for a total transaction of $166,713.75. Following the completion of the purchase, the director now directly owns 5,539,724 shares of the company’s stock, valued at approximately $6,924,655. This represents a 2.47 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.50% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.